Document is current
Any future updates will be listed below
-
Authors
Elomaa, Hanna
Ahtiainen, Maarit
Väyrynen, Sara A.
Ogino, Shuji https://orcid.org/0000-0002-3909-2323
Nowak, Jonathan A.
Friman, Marjukka
Helminen, Olli
Wirta, Erkki-Ville https://orcid.org/0000-0002-2255-6136
Seppälä, Toni T.
Böhm, Jan
Mäkinen, Markus J. https://orcid.org/0000-0002-9200-4118
Mecklin, Jukka-Pekka
Kuopio, Teijo
Väyrynen, Juha P. https://orcid.org/0000-0002-8683-2996
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R35 CA197735)
Syöpäsäätiö (59-5619)
- License Information
-
More Information
Article History
Received: 7 January 2022
Revised: 31 March 2022
Accepted: 4 April 2022
First Online: 21 April 2022
Competing interests
: JAN reports grants from NanoString, Akoya Biosciences and Illumina outside the submitted work. TTS is the CEO and co-owner of Healthfund Finland Oy and reports interview honoraria from Boehringer Ingelheim Finland. The remaining authors declare no competing interests.
: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the hospital administration and the ethics board (Dnro13U/2011, 1/2016 and 8/2020) and the National Supervisory Authority for Welfare and Health (Valvira). The need to obtain informed consent from the study patients was waived (Valvira Dnro 3916/06.01.03.01/2016). The validation study was conducted under permissions form the Ethics Committee of Oulu University Hospital (25/2002, 42/2005, 122/2009, 37/2020) and Biobank Borealis (BB-2017_1012).
: Not applicable.
